Classification of neuropathic pain in cancer patients.
OBJECTIVE
Neuropathic pain can affect up to 40% in patients with cancer, which could be related to the tumour, treatment or comorbid diseases. Effective assessment to diagnose neuropathic pain is crucial in order to choose the right treatment.


RESULTS
There is to date no systematic classification system; the Neuropathic Pain Special Interest Group of the International Association for the Study of Pain developed a neuropathic pain grading system intended to be used for both clinical and research purposes, and a recent review describes a step-by-step process for applying the grading system in a clinical setting for cancer pain.


CONCLUSIONS
We have combined these recommendations to outline a clinically relevant process to classify neuropathic pain in patients with cancer.
aQueen's Centre for Oncology and Haematology, Hull and East Yorkshire Hospitals NHS Trust and Hull York Medical School, University of Hull, Hull bAcademic Unit of Palliative Care, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.
Elaine G
EG
Boland
Matthew R
MR
Mulvey
Michael I
MI
Bennett
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015897:Comorbidity; D006801:Humans; D009369:Neoplasms / Q000150:complications* / Q000503:physiopathology / Q000628:therapy; D009437:Neuralgia / Q000145:classification* / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology; D010149:Postoperative Pain / Q000150:complications* / Q000209:etiology
D000970:Antineoplastic Agents